Literature DB >> 6237623

Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents.

.   

Abstract

UNLABELLED: We randomized 495 men with uncomplicated hypertension (diastolic BP, 92 to 109 mm Hg) to one of five captopril regimens at the following dosages: 12.5 mg three times a day, 25 mg three times a day, 37.5 mg twice daily, 50 mg three times a day, or placebo three times a day. After seven weeks, BP reduction with each captopril dose was greater than in the placebo group, averaging 10.2 to 14.2/8.6 to 10.5 mm Hg. Captopril, 37.5 mg/day, was as effective as 150 mg/day. Hydrochlorothiazide, 25 mg twice daily, was added for seven more weeks to all patients receiving placebo and to two thirds of those randomized to captopril therapy. Blood pressure reduction averaged 12.0/8.7 mm Hg in those receiving hydrochlorothiazide alone and 24.9 to 26.4/14.4 to 17.3 mm Hg in those receiving a combination of hydrochlorothiazide and captopril. Added hydrochlorothiazide greatly enhanced the antihypertensive response. The 15 terminations (4.3%) related to captopril were not life threatening.
CONCLUSION: Captopril treatment of uncomplicated hypertension may be initiated with 37.5 mg/day--half the currently recommended dose.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6237623     DOI: 10.1001/archinte.144.10.1947

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  16 in total

Review 1.  Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?

Authors:  Michael J Osgood; David G Harrison; Kevin W Sexton; Kyle M Hocking; Igor V Voskresensky; Padmini Komalavilas; Joyce Cheung-Flynn; Raul J Guzman; Colleen M Brophy
Journal:  Ann Vasc Surg       Date:  2012-03-22       Impact factor: 1.466

Review 2.  ACE inhibitors and the kidney. A risk-benefit assessment.

Authors:  G Navis; H J Faber; D de Zeeuw; P E de Jong
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

Review 3.  Safety profiles of the angiotensin-converting enzyme inhibitors.

Authors:  N J Warner; J E Rush
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

5.  [Results of a 5-year study with captopril in patients with severe therapy-resistant hypertension].

Authors:  J Schrader; G Schoel; F Scheler
Journal:  Klin Wochenschr       Date:  1986-08-01

Review 6.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 7.  ACE inhibitors in elderly patients with hypertension. Special considerations.

Authors:  M Ravid; D Ravid
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

Review 8.  Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.

Authors:  Balraj S Heran; Michelle My Wong; Inderjit K Heran; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

Review 9.  Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.

Authors:  Kwame N Atuah; Dyfrig Hughes; Munir Pirmohamed
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 10.  Current drug treatment and treatment patterns with antihypertensive drugs.

Authors:  E D Freis; V Papademetriou
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.